FIELD: pharmacology.
SUBSTANCE: invention discloses application of cardiac ouabain glycoside as an antifibrotic agent.
EFFECT: invention allows to expand the range of drugs for treatment of idiopathic pulmonary fibrosis, reduce the number of complications, increase accessibility for patients.
4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIFIBROLYTIC MEANS | 2016 |
|
RU2621299C1 |
| METHOD FOR MANUFACTURING PHARMACEUTICAL COMPOSITION IN FORM OF EXTENDED-RELEASE TABLETS CONTAINING PIRFENIDONE AND USE THEREOF IN REGRESSION OF CHRONIC RENAL INSUFFICIENCY, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS IN HUMANS | 2012 |
|
RU2682177C2 |
| AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2013 |
|
RU2530651C1 |
| DRUG FOR TREATMENT OF TISSUE FIBROSIS BASED ON COMPONENTS OF SECRETOME OF MESENCHYMAL STROMAL CELLS, METHOD FOR OBTAINING AND APPLYING REMEDY | 2020 |
|
RU2766707C1 |
| ORVEPITANT FOR CHRONIC COUGH TREATMENT | 2016 |
|
RU2746601C2 |
| AGENT FOR PULMONARY FIBROSIS CONTAINING PYRAZOLE DERIVATIVE | 2021 |
|
RU2817989C1 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
| ANTAGONISTS OF ENDOTELINE RECEPTOR INTENDED FOR EARLY STAGE OF IDIOPATIC PULMONARY FIBROSIS | 2007 |
|
RU2435585C2 |
| USE OF CHIGLITAZAR AND RELATED COMPOUNDS | 2019 |
|
RU2769446C1 |
